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S U M M A R Y
Crimean–Congo hemorrhagic fever (CCHF) is a viral infection associated with a high mortality rate.
Ribavirin is the only drug used in the treatment of this disease. Studies investigating the effectiveness of
ribavirin in CCHF have been retrospective and to date have included only a small number of cases. In
recent years, due to climate changes, the number of cases of CCHF in Turkey has increased, and
experience in the treatment of CCHF has improved. Several studies have evaluated the efﬁcacy of
ribavirin in Turkey, including one randomized controlled trial and two studies with a large number
of cases. In these studies, ribavirin therapy was not shown to decrease mortality rates; the mortality rate
was 2–9% in patients treated with ribavirin and 5.6–11% in those who were not treated with this drug.
These ﬁndings suggest that patients with CCHF should be followed with supportive care only until
randomized controlled trials with larger groups have been conducted.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Crimean–Congo hemorrhagic fever (CCHF) is a viral infection
seen in Asia, Europe, and the Middle East, and has a high mortality
rate.1,2 CCHF is caused by a virus of the genus Nairovirus, family
Bunyaviridae.1,2 The mortality rate is 3–30% and varies according to
geographic area.1,2 The virus is usually transmitted to humans
through tick bites or direct contact with the blood of an infected
person during the acute phase of the disease.1,2 According to the
World Health Organization, CCHF has been seen in 34 countries,
and more than 50 cases are reported annually in four countries,
including Turkey.3 The tropical climate zone is gradually expand-
ing with the impact of global warming and this has enlarged the
geographic area covered by the ticks that spread the disease.1
The pathogenesis of this disease can be divided into three
phases: pre-hemorrhagic phase, hemorrhagic phase, and conva-
lescent phase.1,2 After transmission of the virus, it replicates and
spreads through the bloodstream and causes ﬂu-like symptoms
lasting for 1 week (pre-hemorrhagic phase).1,2 After this stage, viral
replication decreases, and macrophage-derived cytokines cause
macrophage activation syndrome (hemorrhagic phase). During
this second phase, death may occur due to hemophagocytosis and§ This paper was presented at a poster session of the 5th Eurasia Congress of
Infectious Diseases in Tirana, Albania.
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hemostasis are the most important features of CCHF. DIC is
thought to occur via three mechanisms: increased release of tissue
factor, direct injury, and the release of proinﬂammatory media-
tors.3–5 Increased synthesis of cell surface tissue factor activates
the extrinsic coagulation pathway. A direct injurious effect on the
endothelium and platelets occurs.3,4 Proinﬂammatory mediators
released from virus-infected monocytes lead to destruction of
endothelial cells and platelets.5 DIC presents as a decrease in
clotting factors and platelets.1 In addition, the liver dysfunction
that occurs in the course of the disease contributes to a decrease
in coagulation factors.1 As a result of these events, massive
bleeding can occur in CCHF.1
2. Ribavirin treatment
Although the main treatment option for CCHF is supportive
therapy, ribavirin inhibits viral replication in vivo and has been
shown to reduce death in murine models.6 Ribavirin is a guanosine
analog with broad-spectrum antiviral activity.6 Until recently,
studies supporting the use of ribavirin in CCHF have been
retrospective, with a small number of cases.7–12 Important clinical
questions are emerging due to the increasing number of patients in
our country; also, ribavirin therapy is being evaluated for the
treatment of CCHF. Ribavirin is the only antiviral drug used in CCHF
and its effectiveness remains controversial.7–13 Although some
studies have suggested that the use of ribavirin is effective in CCHF,
others suggest the opposite.7–13 The most well-known study on
ribavirin treatment was conducted in Iran by Mardani et al.7 In thatses. Published by Elsevier Ltd. All rights reserved.
Table 1
CCHF-related mortality rate and ribavirin use in Turkey, 2004–2007
Year Total number of
CCHF patients
Number of patients
using ribavirin
Mortality
rate
2004 249 169 (67.9%) 5.2%
2005 266 58 (21.8%) 4.9%
2006 438 71 (16.2%) 6.2%
2007 717 85 (11.8%) 4.6%
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while seven of 12 patients who were not treated with ribavirin
died (58.3%); this difference was statistically signiﬁcant. However,
the small number of cases in the control group and the
retrospective design of the study may have decreased
the reliability of the results. Mortality rates reported by Mardani
et al. were higher than those in Turkey. This is because the CCHF
strains in Turkey are different from those in Iran.14 In vivo studies
have shown that different CCHF virus strains respond differently to
ribavirin;15 this may explain why patients did not respond well
to ribavirin therapy in Iran.
In contrast to studies in Iran, ribavirin therapy has not been
shown to decrease the mortality rate in Turkey.9–13 In these
studies, the mortality rate was 2–9% in patients treated with
ribavirin and 5.6–11% in patients who were not treated
with ribavirin. There was no difference in terms of mortality,
length of hospital stay, and transfusion of blood products among
the patients treated and not treated with ribavirin.9–11,13 Studies of
the effectiveness of ribavirin in CCHF were retrospective and
included few cases.7–12 Therefore, determining the effectiveness of
ribavirin in CCHF is problematic. Only one randomized controlled
trial evaluating the efﬁcacy of ribavirin has been performed in
Turkey.13 This study compared 64 patients given ribavirin and 72
without treatment. There was no signiﬁcant difference in mortality
rate, proportion of patients requiring platelet transfusion, length of
hospital stay, recovery time, or laboratory parameters. Since 2002,
when the ﬁrst cases were reported in Turkey, the number of cases
of CCHF has increased steadily. Two studies with a large number of
cases showed no change in the course of disease with ribavirin
treatment.16,17 Four hundred patients with CCHF conﬁrmed by PCR
were treated with supportive therapy.16 Twenty (5%) of these
patients died. This mortality rate is similar to that of other studies
of ribavirin for the treatment of CCHF in Turkey.9–11,13 In another
study, the mortality rate of 336 patients taking ribavirin was 7.1%
compared with 7% in 514 patients without treatment (p > 0.05).17
Other studies have suggested that ribavirin is not effective
for the treatment of CCHF.9–13 However, some researchers have
considered ribavirin to be effective, especially when administered
during the early period of the disease.8 Giving ribavirin to patients
during the early and late periods of the disease produces different
results. In one study that included a large number of cases, the
mortality rate in patients who started ribavirin within the ﬁrst
4 days after the onset of symptoms was no different to that of
patients who started treatment later.10 In another study from
Turkey, one of 21 patients treated during the ﬁrst 4 days after the
onset of symptoms died compared to two of 20 patients treated
4 days after the onset of symptoms; this difference was not
signiﬁcant.12 In another study, the initiation of ribavirin in the ﬁrst
4 days after the onset of symptoms was compared with starting
treatment later and was shown to reduce mortality rates from
40% to 15.7% (p = 0.031).8 Again in this study, the mortality rate of
patients receiving ribavirin before bleeding was lower than that
of patients receiving ribavirin later (8% and 35.8%, respectively,
p = 0.018). Reports that ribavirin is more effective during the ﬁrst
period of disease have also concluded that it decreases viral
replication during the ﬁrst week and so reduces the mortality rate.
This hypothesis is supported by the fact that viral load is the most
important factor contributing to mortality in CCHF.18 However, a
study from Turkey contradicts this hypothesis.11 In that study,
10 patients were given ribavirin and 40 were treated with
supportive therapy. In the ﬁrst 6 days of treatment, both viral
load decline and mortality rates were similar in the two groups. In
CCHF, viral load is important for determining the mortality rate,
but ribavirin has not been shown to decrease viral load.
An analysis of studies in Turkey between 2004 and 2007 has
shown a gradual decrease in the use of ribavirin (67.9%, 21.8%,16.2%, and 11.8%); despite this, mortality rates have not changed
signiﬁcantly (5.2%, 4.9%, 6.2%, and 4.6%, respectively) (Table 1).19
This ﬁnding indicates the ineffectiveness of ribavirin.
Although the efﬁcacy of ribavirin in CCHF is highly controver-
sial, its use is justiﬁed based on its being the only drug available.
However, serious side effects are the major obstacle to this
becoming a recommendation. In one study, 126 patients given
ribavirin and 92 patients without treatment were followed;
mortality rates did not differ. However, if only the ﬁrst 8 days
were considered, the mortality rate was 10.3 times higher in those
receiving ribavirin.10 The increased mortality in that study was
related to the toxic effects of ribavirin. In patients with a poor
clinical course, ribavirin can increase the mortality rate due to
severe organ damage. Similarly, in severe acute respiratory
syndrome (SARS), patients with severe hypoxemia treated with
ribavirin had a higher mortality rate due to the effects of the
drug.20 Another obstacle to the use of ribavirin is its genotoxic
effect.21–23 Ribavirin has been shown to have a mutagenic effect on
lymphocytes and sperm.22,23
3. Conclusion
All of these ﬁndings suggest that patients with CCHF should be
followed with supportive care only until randomized controlled
trials including larger populations have been conducted.
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